UPCC 09924 An Open-label, Phase 1/2 Dose-Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 3.1 (Study Objectives). Please refer to Protocol 3.2 (Study Endpoints). Please refer to Protocol 3.2 (Study Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
14 Aug 2024.
Study ID: 855960
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
